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Abstract
Introduction: Activated Protein C [APC] improves outcome in immunocompetent patients with
severe sepsis particularly in those who are perceived to have high mortality risk. Before embarking
on a trial of APC administration in immunocompromised septic patients, a preliminary study on
plasma levels of protein C in this cohort is essential.
Objective:  To assess serum Protein C concentrations in immunocompromised patients as
compared to immunocompetent patients during sepsis, severe sepsis, septic shock and recovery.
Methods: Prospective cohort study in a tertiary hospital. Patients satisfying inclusion criteria were
enrolled after informed consent. Clinical variables were noted with sample collection when patients
met criteria for sepsis, severe sepsis, septic shock and recovery. Protein C levels were measured
using monoclonal antibody based fluorescence immunoassay.
Results:  Thirty one patients participated in this study (22 immunocompromised, 9
immunocompetent). Protein C levels were found to be significantly lower in the
immunocompromised group compared to the immunocompetent group, particularly observed in
severe sepsis [2.27 (95% CI: 1.63-2.9) vs 4.19 (95% CI: 2.87-5.52) mcg/ml] (p = 0.01) and sepsis [2.59
(95% CI: 1.98-3.21) vs 3.64 (95% CI: 2.83-4.45) mcg/ml] (p = 0.03). SOFA scores were similar in
both the groups across sepsis, severe sepsis and septic shock categories. Protein C levels improved
significantly in recovery (p = 0.001) irrespective of immune status.
Conclusion: Protein C levels were significantly lower in immunocompromised patients when
compared to immunocompetent patients in severe sepsis and sepsis categories. Our study suggests
a plausible role for APC in severely septic immunocompromised patients which need further
elucidation.
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Introduction
The role of Protein C pathway in regulating thrombosis,
fibrinolysis and inflammatory cascade in a septic patient
is well established. Both baseline serum protein C and
early reduction in protein C concentrations have been
found to be independent predictors of outcome in severe
sepsis [1,2]. This in combination with blunted generation
of activated Protein C (APC) act in concert with reduced
expression of thrombomodulin to contribute to a proco-
agulant state during sepsis [3,4]. The resulting intravascu-
lar deposition of fibrin and microvascular thrombosis
contributes to the organ dysfunction and mortality in sep-
sis [5]. A phase III randomised controlled trial of activated
protein C (APC) supplementation in severe sepsis
(PROWESS), based on understanding of the pathophysi-
ology, demonstrated a mortality benefit of APC therapy in
severe sepsis that was statistically significant in the sub-
group with protein C deficiency (p = 0.009) compared to
those without protein C deficiency (p = 0.06) [6]. These
findings were supported by the ENHANCE trial [7],
although not by the ADDRESS trial [8]. Of note, in all
these major trials, patients with immunocompromised
states were excluded. One of the main reasons for exclu-
sion of immunocompromised patients was their per-
ceived high risk of bleeding. However, the advent of
newer non-anticoagulant recombinant activated protein
C molecule has allayed some concerns about the risk of
bleeding which is a major drawback of APC as an effective
anti-inflammatory drug [9,10]. Anecdotal evidence sug-
gests that there may be a potential benefit of adding APC
to standard therapy in septic shock after hematopoietic
stem cell transplantation [11]. Preliminary data (Mesters
et al) indicated that plasma protein C concentration
diminished rapidly in the neutropenic patients who
developed septic shock [12]. Thus the question still
remains unresolved whether APC may have a role in the
management of neutropenic sepsis. More fundamentally,
it is not clear whether protein C and APC concentrations
are reduced in immunocompromised sepsis. This study
was therefore designed to assess and compare protein C
levels in immunocompromised patients to immunocom-
petent patients during sepsis, severe sepsis, septic shock
and recovery.
Research design and the methods
This was a single centre prospective cohort study involv-
ing immunocompromised and immunocompetent
patients in the haematology ward and the intensive care
unit of Princess Alexandra Hospital, Brisbane. The study
was approved by the Princess Alexandra Hospital human
research ethics committee and informed consent was
obtained either from patients or their next of kin. All
patients admitted with a diagnosis of sepsis or those who
developed sepsis during their admission were eligible.
Three groups of patients were enrolled for the study:
Immunocompetent patients with sepsis, immunocom-
promised patients with sepsis and immunocompromised
patients without sepsis.
The diagnosis of SIRS, sepsis, severe sepsis and septic
shock were based on standard criteria [13]. Patients were
identified as recovered for the purpose of study when they
no longer satisfied the sepsis criteria for at least 48 hours.
Patients were classified as immunocompromised if they were
diagnosed with neutropenia (absolute count < 0.5 × 109/
L); myeloproliferative or lymphoproliferative condition;
hyposplenism (based on history and imaging) or under-
going chemotherapy.
The exclusion criteria were:
a) Presence of hepatic failure (as protein C is secreted in
hepatic cells)
b) History of spontaneous venous thrombosis and/or pul-
monary embolism
c) Patients on Warfarin (Protein C is a vitamin K depend-
ent protein)
d) Disseminated Intravascular Coagulation (DIC)
e) Patients already on activated protein C infusion
f) Failure to obtain consent
Patients were excluded from the study if they had DIC on
basis of the modified overt diagnostic criteria of ISTH
(International society of thrombosis and hemostasis) sub-
committee on DIC. [14] In absence of any specific DIC cri-
teria particularly for patients with hematopoietic
malignancies and those on chemotherapy [15], we modi-
fied platelet count criteria for myelosuppressed patients to
score 1 if reduction in platelet count by > 30% in last 24
hours not accompanied by similar fall in leucocyte count
and score 2 if reduction in platelet count > 50% platelet in
last 24 hours not accompanied by similar fall in leucocyte
count.
The care of the patients was as per standard practice. No
patient received APC infusion during the study.
Protein C test methodology
Blood for protein C assay was collected in citrated tubes,
double centrifuged before separation of plasma which
was then aliquoted; snap frozen, labelled and stored at -
75°C for assay. Fluorescence Immunoassay (Triage Pro-
tein C Meter, Biosite†) was used for rapid, quantitative
determination of protein C in thawed aliquoted samples.
The mean protein C concentration in healthy men and
women, when tested using the protein C meter, is
reported to be 4.23 μg/ml (median- 4.70 μg/ml) [16]. The
coefficient of variation of the assay is reported to be 2-4%
[17]. To ensure the accuracy, the supplied quality controlJournal of Hematology & Oncology 2009, 2:43 http://www.jhoonline.org/content/2/1/43
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device was run prior to each run of patient's samples. The
test performance was also monitored using external pro-
tein C controls. Five samples (7% of total samples) were
randomly tested twice and their results confirmed the
validity of this commercial assay.
Data collection and Blood sampling
The demographics, APACHE II [18] and SOFA scores [19]
were collected on all patients. Post recruitment, patient's
daily observation charts were closely followed up to assess
if they satisfy criteria for sepsis, severe sepsis, septic shock
or recovery. If patient's clinical condition fits in any of the
abovementioned categories, then serum aliquots (for pro-
tein C assay) were prepared from their morning blood
samples, if collected that day within last 6 hours, or else
protein C test was requested to be done not later than by
next morning. The blood samples were thus collected
within 18 hours of clinical and biochemical observations
that were noted for the purpose of calculating APACHE II
score and SOFA score on all occasions. None of the
patient had repeated sampling/measurements for any
individual septic categories.
Statistical Analysis
All statistical calculations were performed using the Stats-
Direct statistical software package. All continuous varia-
bles were analysed using basic descriptive statistics and
univariate analysis was performed to obtain mean, stand-
ard deviation and/or confidence limits. The variables
between two independent groups (e.g. immunocompro-
mised and immunocompetent) were compared using
unpaired t-test and the data was expressed as mean differ-
ence with 95% confidence interval (CI). A p < 0.05 was
accepted as statistically significant. When the blood sam-
ples and other variables in the immunocompromised
group obtained during different septic categories were
compared against each other, one-way ANOVA for multi-
ple comparison using Tukey-Kramer method (as unequal
group sizes) was used.
Results
Thirty eight patients were found to be eligible over a
period of four months. Two patients were from non-Eng-
lish background and were excluded. Five patients refused
consent. Thirty one patients participated in the study (22
Immunocompromised and 9 Immunocompetent).
a) Immunocompetent patients with sepsis (n = 9)
b) Immunocompromised patients with sepsis (n = 16)
c) Immunocompromised patients without sepsis (n = 6)
Table 1 shows the demographic data and the aetiologies
of sepsis in all three groups. The groups were well
matched in terms of age and the length of hospital stay.
The causes for low immunity in the immunocompro-
mised group were neutropenia (16/22), lymphoprolifera-
tive condition (4/22), hyposplenism (1/22) and
minimally myelosuppressive chemotherapy (1/22). Five
patients included in the neutropenia group were on mye-
losuppressive chemotherapy.
Breakdown of Septic episodes
Among the immunocompromised septic patients (n =
16), 7 patients developed sepsis, 11 patients developed
severe sepsis and 2 progressed to develop septic shock.
The corresponding figures for the immunocompetent sep-
tic group (n = 9 patients) were 8, 6 and 3 respectively.
None of the patient was represented more than once in
any of the individual septic category.
There were two deaths among study patients, one of
which was in the immunocompromised severe sepsis cat-
egory and other one was in the immunocompromised
septic shock category.
Protein C concentration
Table 2 provides comparative data in the immunocom-
promised cohort measured during non-sepsis, sepsis,
severe sepsis, septic shock and recovery. There was a statis-
tically significant reduction in protein C concentrations in
sepsis- 2.59 (95% CI: 1.98- 3.21) μg/ml [p = 0.03], severe
sepsis- 2.27 (95% CI: 1.63- 2.9) μg/ml [p = 0.001] and
septic shock - 1.23 μg/ml, when compared to values dur-
ing recovery - 3.82 (95% CI: 3.23- 4.40) μg/ml. Moreover,
there was no statistically significant difference between
the protein C concentrations during recovery and non-
sepsis - 3.96 (95% CI: 2.51- 5.41) μg/ml. Protein C levels,
APACHE II scores and SOFA scores were similar across
non-sepsis and recovery categories. Although, fibrinogen
levels were elevated in sepsis, severe sepsis and septic
shock, these did not reach statistical significance.
Comparison of immunocompromised sepsis vs 
immunocompetent sepsis
Serum protein C concentrations were found to be signifi-
cantly lower in the immunocompromised group com-
pared to the immunocompetent group, particularly
observed in severe sepsis [2.27 (95% CI: 1.63-2.9) vs 4.19
(95% CI: 2.87-5.52) μg/ml] (p = 0.01) and sepsis [2.59
(95% CI: 1.98-3.21) vs 3.64 (95% CI: 2.83-4.45) μg/ml]
(p = 0.03). The results are summarised in Table 3.
Sickness severity
SOFA scores were similar in both the groups across sepsis,
severe sepsis and septic shock categories. Of note, the sta-
tistically significant difference in APACHE II scores
between the immunocompromised and the immuno-
competent groups should be looked at in light of the fact
that all immunocompromised patients gained 5 extra
points on chronic health adjustment (on account of beingJournal of Hematology & Oncology 2009, 2:43 http://www.jhoonline.org/content/2/1/43
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immunosuppressed) while calculating APACHE II scores
and thus it does not imply any significant difference in the
level of sickness among the two groups.
Discussion
The principal finding of this study was that the plasma
protein C concentrations in the immunocompromised
septic patients were lower than those seen in the immuno-
competent septic patients and the protein C levels
improved with recovery. To our knowledge, this study
represents the first clinical trial investigating protein C lev-
els in immunocompromised patients as compared to
immunocompetent patients across different septic catego-
ries.
Mechanism of Protein C reduction in Sepsis
Protein C is an important component of the natural anti-
coagulant pathway. Under resting physiological condi-
tions, protein C is continuously activated to maintain an
anticoagulant milieu [20]. Severe sepsis is known to cause
generalized endothelial dysfunction resulting in a pro-
coagulant state in the microvasculature [21,22]. The acti-
vated coagulation cascade results in thrombin formation
which then binds to thrombomodulin (TM). TM bound
thrombin cause proteolysis of protein C and convert it to
activated protein C (APC) which then down-regulates
thrombin formation in negative feedback loop [23]. This
activation of protein C is augmented by 20 fold in the
presence of endothelial protein C receptor (EPCR) [24]
which is known to have increased plasma concentrations
in septic patients [25]. This interaction is a critical step in
the host defence against sepsis since inhibition of protein
C binding to EPCR (in baboon model) is shown to con-
vert the response to sublethal concentrations of E.coli into
a lethal response [26]. Protein C is thus consumed during
development of severe sepsis thereby contributing further
to the development of microvascular thrombosis and dis-
seminated intravascular coagulation. Moreover, the
cytokine response in sepsis may also result in decreased
expression levels of TM and EPCR on endothelium and
thus decreased activation of protein C [27]. These mecha-
nisms may explain the reduction in plasma protein C con-
centrations in severe sepsis observed in our study.
However, our data indicates that plasma protein C levels
are even lower in immunocompromised septic patients
compared to the immunocompetent septic patients. There
are various plausible mechanisms. A link between the pro-
tein C anticoagulant pathway and neutrophil functions is
suggested by the observation that the soluble EPCR binds
to activated neutrophils via Proteinase-3 and this binding
is supported by β2 integrin involved in neutrophil signal-
Table 1: Demographics in both groups of patients
Immunocompromised Immunocompetent
Non-Sepsis Sepsis
n6 1 69
Age in years (Range) 59
(29-74)
63.5
(45-81)
54
(22-72)
Females % 66% 25% 44%
Hospital stay
(SD*)
17.3 days
(15.4)
21.7 days
(16.1)
24.9 days
(18.9)
Source of Sepsis
Pneumonia (CAP§)2 3
Nosocomial Pneumonia 1 1
Abdominal sepsis - 1
Urosepsis - 1
Soft tissue infection 1 2
Bacteremia 5 1
FUO (Fever of unknown origin)Φ 7-
Micro-organisms
Gram positives Staph aureus (2)# Staph aureus (1)#
Staph hemolyticus (3) Staph epidermidis (1)
Gram negatives E.coli (1) E. coli (2)
Pseudomonas (1) Pseudomonas (1)
Klebsiella (1) Legionella (1)
Enterobacter cloacae (1) Citrobacter koseri (1)
Fungus Candida albicans (1) Candida albicans (1)
* Standard Deviation, § Community acquired pneumonia
 Positive blood cultures some of which were related to catheter-related blood stream infections.
ΦFUO was considered when patients had persistent fevers despite intensive evaluation and diagnostic testing for more than a week as an inpatient 
in the hospital.
# (n) Number of patients in whom the specified micro-organism was incriminated as a cause of sepsis.Journal of Hematology & Oncology 2009, 2:43 http://www.jhoonline.org/content/2/1/43
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ling and cell-cell adhesion events [28]. It is possible that
these molecular interactions are significantly affected by
haematological malignancies, neutropenia or endothelial
dysfunction induced by cytotoxic drugs thereby further
impairing the protein C system in our immunocompro-
mised septic patients. Most of our patients in the immu-
nocompromised cohort had received chemotherapy at
some stage for their underlying haematological condition.
Chemotherapy has been shown to induce endothelial
dysfunction that was observed in young adult survivors
treated for acute lymphoblastic leukaemia in childhood
[29,30] Malignancies and chemotherapy induced
endothelial dysfunction might have predisposed our
immunocompromised septic patients to have higher inci-
dence of non-overt DIC resulting in increased consump-
tion of protein C. It is also possible that protein C
synthesis failed to keep up during the critical illness par-
ticularly when patients were on chemotherapy. Chemo-
therapy for breast cancer is known to decrease protein C
concentrations [31]. Doxorubicin has been shown to
induce dose and time dependent decrease in cell surface
EPCR levels and increase in cell surface thrombomodulin
in human umbilical vein endothelial cells (HUVEC) with
a net effect of impaired capacity of HUVECs to convert
protein C to activated protein C [32]. Since, activation of
protein C system largely depends on TM and EPCR, it is
important to study TM expression and EPCR expression in
immunocompromised patients during non-sepsis state
and in face of septic challenge in future studies. Other
mechanisms that should be investigated are protein C
consumption primarily due to DIC or reduced synthesis
due to liver dysfunction. We excluded patients with overt
DIC in this study and there were no significant differences
between the two groups with respect to prothrombin time
and bilirubin concentrations during any of the septic cat-
egories (Table 3).
Possible Clinical significance of these results
The significance of protein C arises from published litera-
ture on activated protein C. Whilst we did not measure
APC in this study, it is well recognised that circulating lev-
els of APC strongly correlate (r = 0.75, p < 0.0001) with
levels of protein C antigen in both healthy men and indi-
viduals with protein C deficiency suggesting that the circu-
lating protein C concentration is the limiting factor in the
rate of activation of protein C [33]. Therefore, protein C
levels may reliably reflect APC levels in vivo.
Table 2: Observations during sepsis, severe sepsis and septic shock in the immunocompromised cohort as compared to observations 
during recovery
Variables Immuno-
compromised 'Non 
Sepsis'
Immuno-
compromised 
'Sepsis'
Immuno-
compromised 
'Severe sepsis'
Immuno-
compromised 
'Septic shock'
Immuno-
compromised 
'Recovery'
'n' 6 71 121 3
Age (Range) 59 (29-74) 62 (45-81) 64 (57- 74) 64 59.5 (33- 81)
Protein C level in 
μg/ml (CL*)
3.96
(2.51- 5.41)
2.59
(1.98-3.21)
p§- 0.031
2.27
(1.63- 2.9)
p§- 0.0011
1.23 3.82
(3.23- 4.40)
SOFA score (CL*) 2.3
(0.6- 4.1)
2.9
(0.9- 4.7)
p§- 0.94
4.6
(3.5- 5.6)
p§- 0.024
12.5 2.4
(1.4- 3.4)
APACHE II score 
(CL*)
13.2
(9.8- 16.6)
14.6
(13.5- 15.6) p§- 0.233
17.6
(15.7- 19.6) p§- 0.0004
28 11.8
(9.8- 13.8)
Fibrinogen level in 
g/l (CL*)
2.94
(2.15- 3.73)
5.41
(3.34- 7.49)
p§- 0.68
5.54
(3.63- 7.45)
p§- 0.51
8.65 4.26
(3.53- 4.98)
WBC (× 109/l) 1.16 4.94 0.5 0.9 4.7
Platelets (× 109/l) 61.8 88.3 21.5 77.5 83
* Confidence limits (in brackets)
§ p- p Value obtained when variables during different septic categories were compared to observations during recovery. There was no statistical 
difference among the variables (Protein C, APACHE II & SOFA scores) measured during non-sepsis and recovery.
p values for the septic shock cohort have not been provided because of the small sample numbers.Journal of Hematology & Oncology 2009, 2:43 http://www.jhoonline.org/content/2/1/43
Page 6 of 8
(page number not for citation purposes)
Study Limitations
This was a single centre study with small sample size. APC
and other coagulation factors were not measured along
with protein C. Moreover, the possible mechanisms of
reduction in protein C such as soluble EPCR -neutrophils
interaction in the immunocompromised patients, non-
overt DIC scores and TM concentrations were not investi-
gated and lastly, the relationship between protein C con-
centrations and outcome could not be examined owing to
the small sample size.
Conclusion
This preliminary study reveals significantly lower protein
C levels in the immunocompromised patients during sep-
sis and severe sepsis as compared to the immunocompe-
tent patients. There was a significant improvement in
protein C levels with recovery in both groups of patients.
Further studies are required to confirm the findings of our
study in a larger setting, and investigate relationship
between protein C concentrations and outcome in immu-
nocompromised septic patients. Our pilot study might
provide the platform for a future clinical trial designed to
study benefits of activated protein C therapy in the immu-
nocompromised septic patients.
Table 3: Observations in the immunocompromised and the immunocompetent cohorts during Sepsis, Severe Sepsis and Septic Shock
Variables Sepsis Severe Sepsis Septic Shock
Immuno-
compromised
Immuno-
competent
Immuno-
compromised
Immuno-
competent
Immuno-
compromised
Immuno-
competent
'n'§ 78 1 1 623
Age (Range) 62 (45-81) 56 (22-72) 64 (57-74) 53 (22-72) 64 65
Protein C level 
in μg/ml 
(CL)
2.59*
(1.98- 3.21)
3.64*
(2.83- 4.45)
2.27**
(1.63- 2.9)
4.19**
(2.87- 5.52)
1.23 2.79
SOFA score
(CL)
2.9
(0.9- 4.7)
2
(0.7- 3.3)
4.6
(3.5- 5.6)
4.3
(2.4- 6.3)
12.5 8.3
APACHE II 
score 
(CL)
14.6***
(13.5- 15.6)
8.5***
(4.8- 12.2)
17.6
(15.7- 19.6)
14.3
(10.3- 18.4)
28 22
Fibrinogen level 
in g/l 
(CL)
5.41
(3.34- 7.49)
5.9
(2.19- 9.61)
5.54
(3.63- 7.45)
5.13
(2.01- 8.24)
8.65 7.9
WBC (× 109/l) 4.94 13.8 0.5 17.6 0.9 31.2
Platelets (× 109/
l)
88.3 412.4 21.5 267.5 77.5 243.3
PTΦ 12δ 10.9δ 13.1 13.2 16 16
Bilirubinξ
(in μmol/l)
18.9π 11.5π 18.4ω 17.8ω 31.5 29
* p = 0.03, 95% CI (Mean Difference) = -1.97 to -0.1 and ** p = 0.01, 95% CI (Mean Difference) = -3.28 to -0.57, P value for difference in the 
Protein C levels between immunocompromised group and immunocompetent group during sepsis and severe sepsis respectively.
*** p = 0.006, P value for difference in APACHE II scores between immunocompromised group and immunocompetent group, when compared 
during 'sepsis'.
PT Φ - Mean Prothrombin time (seconds). Normal reference range for the laboratory is 9-12 seconds.
δ p = 0.1, P value for difference in mean prothrombin time between two groups during sepsis.
Bilirubin ξ - Normal reference range for the laboratory is 5-17 μmol/l. π p = 0.1; ω p = 0.9; P value for difference in mean bilirubin levels between two 
groups during sepsis and severe sepsis.
p values for the septic shock cohort have not been provided because of the small sample numbers.
'n'§- Number of patients in each of the septic category. (Patients could be in more than one category depending on whether they developed sepsis, 
severe sepsis or septic shock. Hence, total number of septic episodes is more than total number of patients.)
CL - Confidence limitsJournal of Hematology & Oncology 2009, 2:43 http://www.jhoonline.org/content/2/1/43
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Key Messages
￿ Plasma protein C concentrations in immunocom-
promised patients are lower than immunocompetent
patients, particularly observed in sepsis and severe
sepsis.
￿ Protein C levels improved significantly with recovery
irrespective of immune status.
￿ The study suggests a plausible role for APC in
severely septic immunocompromised patients which
need further elucidation in a randomized controlled
clinical trial.
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